Secreted and transmembrane polypeptides and nucleic acids encoding the same

Abstract

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

1 - 71 . Canceled.  
     
     
         72 . A diagnostic method, comprising determining, in a test biological sample obtained from a mammalian subject, the level of nucleic acid encoding a PRO353 polypeptide of SEQ ID NO:372 relative to the level of said nucleic acid in a corresponding normal biological sample wherein increased level of said nucleic acid in the test biological sample is indicative that the test biological sample contains cancerous cells.  
     
     
         73 . The method of  claim 72  wherein the test and normal biological samples are tissue samples.  
     
     
         74 . The method of  claim 73  wherein the test tissue sample is from breast or lung tissue.  
     
     
         75 . The method of  claim 74  wherein the normal biological sample is from the same type of tissue as the test biological sample.  
     
     
         76 . The method of  claim 74  wherein the normal biological sample is an epithelial tissue sample from a combination of tissues.  
     
     
         77 . The method of  claim 76  wherein epithelial tissue sample includes epithelial cells from breast and lung tissue.  
     
     
         78 . The method of  claim 72  wherein the nucleic acid levels are determined by hybridization of nucleic acid obtained from the test and normal biological samples to one or more probes specific for the nucleic acid encoding PRO353.  
     
     
         79 . The method of  claim 78  wherein hybridization is performed under stringent conditions.  
     
     
         80 . The method of  claim 79  wherein said stringent conditions use 50% formamide, 5×SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC and 50% formamide at 55° C., followed by a wash comprising of 0.1×SSC containing EDTA at 55° C.  
     
     
         81 . The method of  claim 78  wherein the nucleic acids obtained from the test and normal biological samples are cDNAs.  
     
     
         82 . The method of  claim 81  wherein the nucleic acids obtained from the test and normal biological samples are placed on microarrays.  
     
     
         83 . A diagnostic method comprising determining the expression level of the PRO353 polypeptide of SEQ ID NO:372 in test biological sample relative to a normal biological sample, wherein overexpression of said polypeptide in the test biological sample is indicative that the sample contains cancerous cells.  
     
     
         84 . The method of  claim 83  wherein the test and normal biological samples are tissue samples.  
     
     
         85 . The method of  claim 84  wherein the test tissue sample is from breast or lung tissue.  
     
     
         86 . The method of  claim 83  wherein overexpression is detected with an antibody that specifically binds to the PRO353 polypeptide.  
     
     
         87 . The method of  claim 86  wherein said antibody is a monoclonal antibody.  
     
     
         88 . The method of  claim 87  wherein said antibody is a humanized antibody.  
     
     
         89 . The method of  claim 87  wherein said antibody is an antibody fragment.  
     
     
         90 . The method of  claim 87  wherein said antibody is labeled.